Latanotim-Vision (Timolol Maleate, Latanoprost)

• Latanotim-Vision combines a beta‑blocker and a prostaglandin analog to manage conditions that involve elevated intraocular pressure.
• Open-angle glaucoma: reduces intraocular pressure to protect the optic nerve and preserve vision.
• Ocular hypertension: lowers pressure to prevent progression to glaucoma.
• Secondary glaucoma (e.g., steroid‑induced): helps control pressure when other agents are insufficient.

• Timolol maleate non‑selectively blocks beta‑adrenergic receptors in the ciliary body, decreasing aqueous humor production. Latanoprost, a prostaglandin F2α analogue, binds FP receptors to remodel the extracellular matrix, enhancing uveoscleral outflow. The combined actions result in a net reduction of intraocular pressure, addressing the primary pathogenic factor in glaucoma and ocular hypertension.

Latanotim-Vision may cause ocular and systemic reactions.

Common Side Effects

• Blurred vision: transient visual disturbance after instillation.
• Eye irritation or burning: mild discomfort on application.
• Conjunctival hyperemia: redness of the eye.
• Increased eyelash growth: longer, thicker lashes.
• Darkening of iris color: gradual pigmentation change.
• Periorbital skin darkening: mild hyperpigmentation around the eye.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Persistent eye pain: may indicate corneal involvement.
• Sudden loss of vision: requires immediate medical attention.
• Systemic bradycardia: slowed heart rate in susceptible patients.
• Respiratory distress: bronchospasm in patients with asthma.
• Acute angle‑closure glaucoma: rapid increase in intraocular pressure.

Before prescribing Latanotim-Vision, clinicians should consider patient‑specific factors and safety measures.

• Assess cardiovascular status: avoid in patients with severe bradycardia or heart block.
• Evaluate respiratory history: contraindicated in uncontrolled asthma or severe COPD.
• Review ocular conditions: use with caution in patients with narrow anterior chamber angles.
• Monitor intraocular pressure: regular measurements to ensure therapeutic effect.
• Inform about iris color change: discuss potential permanent pigmentation.
• Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanotim-Vision can interact with systemic and ocular agents, influencing efficacy or safety.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers (e.g., propranolol): additive bradycardia and hypotension.
• Other prostaglandin analog eye drops: increased risk of ocular hyperemia and irritation.

Moderate Interactions (Monitor Closely)

• Topical anesthetics: may exacerbate ocular surface irritation.
• Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): enhanced intraocular pressure reduction.
• Anticholinergic eye drops: potential reduction in aqueous humor outflow.
• Nasal decongestants (e.g., phenylephrine): may counteract beta‑blocker effects on ocular vessels.